Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Surges 28% Yet Its Low P/S Is No Reason For Excitement
Positive Outlook for Arcturus Therapeutics' Vaccine Production and Distribution Spurs Buy Rating
Unveiling 3 Analyst Insights On Arcturus Therapeutics
H.C. Wainwright Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $63
Arcturus Therapeutics Price Target Maintained With a $63.00/Share by HC Wainwright & Co.
Wells Fargo Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $58